<DOC>
	<DOCNO>NCT01972984</DOCNO>
	<brief_summary>1 . Women operable breast cancer 2-8 week preoperative waiting period accept preoperative therapy trial specifically take standard drug breast cancer anastrozole study 2 . Short term anastrozole treatment induce measurable change biomarker level ( ER , PR , Her2 , Ki67 ) within tumor . 3 . Degree response short term anastrozole varies ) duration treatment b ) breast cancer subtype ( base initial pre-treatment biomarker status )</brief_summary>
	<brief_title>Feasibility Study Presurgical Hormone Therapy ( Anastrozole ) Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>1 . Newly diagnose postmenopausal woman ( Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g. , age appropriate , history vasomotor symptom ) six month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL estradiol &lt; 20 pg/mL surgical bilateral oophorectomy ( without hysterectomy ) least six week ago . ) 2 . Confirmation estrogen receptor positive invasive carcinoma core biopsy 3 . Patients whose cancer palpable deem `` operable '' surgeon 4 . Surgery plan next 28 week . 1 . History hormone replacement therapy last 6 month 2 . Previous treatment tamoxifen aromatase inhibitor treatment six month 3 . Known hypersensitivity contraindication aromatase inhibitor 4 . Known metastatic disease presentation 5 . Recurrent breast cancer 6 . Inability give inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Estrogen receptor positive</keyword>
</DOC>